Abstract 428: Positive correlation of beta1 integrin expression and prognosis in clinically localized prostate cancer

• Published in: Cancer research (Chicago, Ill.) Ill.), 2011-04, Vol.71 (8_Supplement), p.428-428
• Main Authors: Jr, Jose Pontes, Ribeiro-Filho, Leopoldo Alves, dos Reis, Sabrina T., Timoszczuk, Luciana, Bernardes, Felipe S., Antunes, Alberto A., Viana, Nayara I., Passerotti, Carlo C., Oliveira, Luiz CN, Hagopian, Ellen, Dall'Oglio, Marcos F., Leite, Katia RM, Srougi, Miguel
• Format: Article
• Language: English
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/1538-7445.AM2011-428

Introduction and objective: Integrins are transmembrane glycoprotein receptors that regulate cell-matrix interactions, functioning as sensors of the environment. They also act as cell adhesion molecules, being responsible for the maintenance of the epithelial phenotype. Some studies have reported correlation between alterations of integrins expression and carcinogenesis, specially β1 integrin, but their role in prostate cancer is unclear. Our aim is to study the expression of β1 integrin and evaluate its association with recurrence of prostate cancer after surgical treatment Methods: For this case-control study, we selected 111 patients with localized tumor submitted to radical prostatectomy by the same surgeon. 60 of these patients have not presented recurrence after a median follow-up of 123 months. Recurrence was defined as a PSA level above 0.4ng/ml. Integrin expression was evaluated by immunohistochemistry in a Tissue Microarray containing two samples from each tumor. We employed a semiquantitative analysis and considered a case as positive when the expression was strong and diffusely present. We correlated expression with recurrence employing the χ2 test and p